title: FDA Policy and Cardiovascular Medicine.
authors.affiliation: From Section of General Internal Medicine and the Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine; Department of Health Policy and Management, Yale University School of Public Health; and Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (J.S.R.); and Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (A.S.K.). joseph.ross@yale.edu.
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Ross
authors.affiliation: From Section of General Internal Medicine and the Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine; Department of Health Policy and Management, Yale University School of Public Health; and Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (J.S.R.); and Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (A.S.K.).
authors.forename: Aaron S
authors.initials: AS
authors.lastname: Kesselheim
mesh_terms: D001688:Biological Products; D002309:Cardiology / Q000639:trends*; D002318:Cardiovascular Diseases / Q000628:therapy*; D015510:Clinical Medicine / Q000639:trends*; D017277:Drug Approval; D016568:Drugs, Generic; D004869:Equipment Safety; D006291:Health Policy / Q000639:trends*; D006801:Humans; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration / Q000639:trends*
chemical_list: D001688:Biological Products; D016568:Drugs, Generic
keywords: health policy; medical therapy; pharmaceutical safety